US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Bindex measurement revolutionizes osteoporosis diagnostics in US – one million patients have been measured in just 18 months.

Press release     Nov 26, 2018Bone Index Ltd., a medical device company with game-changing point-of-care technology (Bindex®) in osteoporosis diagnostics, announces that one million patients have been measured with Bindex® in the U.S. in 2018. Earlier this year, the American Medical Association issued a new reimbursement code* for Bindex® and the Centers for Medicare & Medicaid Services (CMS) has approved coverage for the code in several settings. “One million is a huge milestone for our company and the unique Bindex® technology. We have exceeded our own and our customers’ expectations.

Bone Index Ltd. Announces Medicare Reimbursement Coverage for Bindex Osteoporosis Measurement

Bone Index Ltd., a medical device company with a game changer point-of-care technology (Bindex®) in osteoporosis diagnostics, announces that U.S. Centers for Medicare & Medicaid Services (CMS) has approved coverage for Bindex® measurement in the Ambulatory Surgical Center (ASC) setting, when provided integral to a surgical procedure on ASC list*. In addition, the coverage includes the outpatient hospital settings*. “This significant reimbursement coverage is a remarkable milestone for Bindex measurement. In addition, this is a great example how CMS wants to improve the healthcare in US.

A Study confirms - Bindex ® point-of-care technology is extremely cost-effective in osteoporosis management

A new study* published in ClinicoEconomics and Outcomes Research reveals the immense cost-effectiveness and cost savings of Bindex® point-of-care device in osteoporosis management pathway. In this parallel study, Bindex was implemented in the traditional management pathway and the new pathway was compared to the traditional one. “This is a great evidence how unprecedented new technology will improve the healthcare system performance. The key is how the new technology will simplify the treatment pathways in the modern healthcare. With Bindex, we can notably improve the access for the

A Study confirms - Bindex ® point-of-care technology is extremely cost-effective in osteoporosis management

A new study* published in ClinicoEconomics and Outcomes Research reveals the immense cost-effectiveness and cost savings of Bindex® point-of-care device in osteoporosis management pathway. In this parallel study, Bindex was implemented in the traditional management pathway and the new pathway was compared to the traditional one. “This is a great evidence how unprecedented new technology will improve the healthcare system performance. The key is how the new technology will simplify the treatment pathways in the modern healthcare. With Bindex, we can notably improve the access for the

Bone Index Ltd. Announces American Medical Association Issues New Reimbursement Code for Bindex osteoporosis measurement

Bone Index Ltd., one of Europe's top new manufacturers of medical devices, announces that the American Medical Association (AMA) has issued a new Category III CPT® code* for Bindex® measurement to help physicians in diagnosing osteoporosis. “In osteoporosis screening and diagnostics area, it has taken about 20 years since the last new code and therefore this new CPT code is a huge step for healthcare operators to provide highly needed osteoporosis examinations. This is also very strong evidence that Bindex is a new and unique medical device which provides significant improvement in

There are no items matching the current filter
There are no more items matching the current filter
Back to top